Skip to content
OpenCapital
Get started

InfuSystem Holdings INFU Indefinite-Lived Research and Development Assets

Indefinite-Lived Research and Development Assets at other companies

ICU Medical logo
ICU MedicalICUI
——
Tenet Healthcare logo
Tenet HealthcareTHC
——

Other financials

Income statement

See full
Revenue$33.7M-3.0%
Gross profit$19.7M+2.7%
Operating income$1.6M+157%
Net income$1.0M+481%
EPS (diluted)$0.05+600%

Balance sheet

See full
Cash & equivalents$2.1M+39.8%
Total debt$24.1M-30.4%
Total equity$58.7M+6.5%
Total assets$98.7M-5.4%

Cash flow

See full
Operating cash flow$970.0K-45.5%
CapEx$157.0K+19.8%
Free cash flow$813.0K-50.7%

Valuation

See full
Market cap$205.05M+51.3%
Enterprise value$227.04M+36.2%
P/E25.9×-0.8×
P/S1.4×+0.5×

Profitability

See full
Gross margin56.7%+3.6pp
Operating margin9.1%+3.0pp
Net margin5.6%+3.2pp
FCF margin16.2%+1.0pp

Returns & leverage

See full
Return on equity13.9%+8.0pp
Debt / equity0.4×-0.2×
Current ratio2.1×-0.1×

Where this comes from

Reported directly by InfuSystem Holdings in its filing.

Tagged under the XBRL concept us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill.

The official record: InfuSystem Holdings’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →

Ask your AI about InfuSystem Holdings's indefinite-lived research and development assets.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is InfuSystem Holdings's indefinite-lived research and development assets?
InfuSystem Holdings (INFU) reported indefinite-lived research and development assets of $2M in Q1 2026.
How has InfuSystem Holdings's indefinite-lived research and development assets changed year-over-year?
InfuSystem Holdings's indefinite-lived research and development assets decreased by 0.0% year-over-year, from $2M to $2M.
What is the long-term trend for InfuSystem Holdings's indefinite-lived research and development assets?
Over 5 years (2020 to 2025), InfuSystem Holdings's indefinite-lived research and development assets has grown at a 0.0% compound annual growth rate (CAGR), from $2M to $2M.